Targeting Targeted Therapy
作者： Mark R. Green
DOI: 10.1056/NEJME048101
关键词: Chemotherapy 、 Lymphoma 、 Targeted therapy 、 Gestational choriocarcinoma 、 Lung cancer 、 Oncology 、 Childhood Acute Lymphoblastic Leukemia 、 Disease 、 Internal medicine 、 Adverse effect 、 Medicine
摘要: The emergence of effective cancer chemotherapy is one of the major medical advances of the second half of the 20th century. In certain neoplasms — such as gestational …
sci-hub.se 参考文章(9)
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
Giuseppe Giaccone, Roy S. Herbst, Christian Manegold, Giorgio Scagliotti, Rafael Rosell, Vincent Miller, Ronald B. Natale, Joan H. Schiller, Joachim von Pawel, Anna Pluzanska, Ulrich Gatzemeier, John Grous, Judith S. Ochs, Steven D. Averbuch, Michael K. Wolf, Pamela Rennie, Abderrahim Fandi, David H. Johnson, Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1 Journal of Clinical Oncology. ,vol. 22, pp. 777- 784 ,(2004) , 10.1200/JCO.2004.08.001
Charles L Vogel, Melody A Cobleigh, Debu Tripathy, John C Gutheil, Lyndsay N Harris, Louis Fehrenbacher, Dennis J Slamon, Maureen Murphy, William F Novotny, Michael Burchmore, Steven Shak, Stanford J Stewart, Michael Press, Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer Journal of Clinical Oncology. ,vol. 20, pp. 719- 726 ,(2002) , 10.1200/JCO.20.3.719
Mark G. Kris, Ronald B. Natale, Roy S. Herbst, Thomas J. Lynch, Jr, Diane Prager, Chandra P. Belani, Joan H. Schiller, Karen Kelly, Harris Spiridonidis, Alan Sandler, Kathy S. Albain, David Cella, Michael K. Wolf, Steven D. Averbuch, Judith J. Ochs, Andrea C. Kay, Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial JAMA. ,vol. 290, pp. 2149- 2158 ,(2003) , 10.1001/JAMA.290.16.2149
J. Baselga, D. Rischin, M. Ranson, H. Calvert, E. Raymond, D.G. Kieback, S.B. Kaye, L. Gianni, A. Harris, T. Bjork, S.D. Averbuch, A. Feyereislova, H. Swaisland, F. Rojo, J. Albanell, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types Journal of Clinical Oncology. ,vol. 20, pp. 4292- 4302 ,(2002) , 10.1200/JCO.2002.03.100
Roy S. Herbst, Giuseppe Giaccone, Joan H. Schiller, Ronald B. Natale, Vincent Miller, Christian Manegold, Giorgio Scagliotti, Rafael Rosell, Ira Oliff, James A. Reeves, Michael K. Wolf, Annetta D. Krebs, Steven D. Averbuch, Judith S. Ochs, John Grous, Abderrahim Fandi, David H. Johnson, Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 Journal of Clinical Oncology. ,vol. 22, pp. 785- 794 ,(2004) , 10.1200/JCO.2004.07.215
Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Jean-Yves Douillard, Yutaka Nishiwaki, Johan Vansteenkiste, Shinzoh Kudoh, Danny Rischin, Richard Eek, Takeshi Horai, Kazumasa Noda, Ichiro Takata, Egbert Smit, Steven Averbuch, Angela Macleod, Andrea Feyereislova, Rui-Ping Dong, José Baselga, None, Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 21, pp. 2237- 2246 ,(2003) , 10.1200/JCO.2003.10.038
Dennis J. Slamon, Brian Leyland-Jones, Steven Shak, Hank Fuchs, Virginia Paton, Alex Bajamonde, Thomas Fleming, Wolfgang Eiermann, Janet Wolter, Mark Pegram, Jose Baselga, Larry Norton, Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 The New England Journal of Medicine. ,vol. 344, pp. 783- 792 ,(2001) , 10.1056/NEJM200103153441101
Barsky Sh, Grossman Da, Ho J, Holmes Ec, The multifocality of bronchioloalveolar lung carcinoma: evidence and implications of a multiclonal origin. Modern Pathology. ,vol. 7, pp. 633- ,(1994)